Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Given Consensus Recommendation of “Buy” by Brokerages

Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) have been given a consensus recommendation of “Buy” by the twelve analysts that are presently covering the stock, MarketBeat reports. Ten equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating on the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $56.27.

Several brokerages have issued reports on MIRM. JPMorgan Chase & Co. increased their price target on Mirum Pharmaceuticals from $31.00 to $39.00 and gave the stock an “overweight” rating in a report on Tuesday, June 18th. Morgan Stanley lifted their price objective on shares of Mirum Pharmaceuticals from $53.00 to $57.00 and gave the stock an “overweight” rating in a research report on Tuesday, June 18th. HC Wainwright reissued a “buy” rating and issued a $66.00 price objective on shares of Mirum Pharmaceuticals in a report on Friday, July 26th. Baird R W raised Mirum Pharmaceuticals to a “strong-buy” rating in a report on Monday, June 17th. Finally, JMP Securities boosted their price objective on shares of Mirum Pharmaceuticals from $66.00 to $68.00 and gave the company a “market outperform” rating in a research note on Tuesday, June 18th.

Institutional Investors Weigh In On Mirum Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Quest Partners LLC boosted its position in Mirum Pharmaceuticals by 7,513.3% in the 2nd quarter. Quest Partners LLC now owns 1,142 shares of the company’s stock valued at $39,000 after buying an additional 1,127 shares during the period. Amalgamated Bank boosted its position in shares of Mirum Pharmaceuticals by 60.8% in the 2nd quarter. Amalgamated Bank now owns 1,357 shares of the company’s stock worth $46,000 after purchasing an additional 513 shares in the last quarter. StepStone Group LP acquired a new position in Mirum Pharmaceuticals during the 4th quarter valued at about $135,000. ProShare Advisors LLC purchased a new stake in Mirum Pharmaceuticals in the second quarter valued at about $213,000. Finally, NEOS Investment Management LLC acquired a new stake in Mirum Pharmaceuticals in the fourth quarter worth about $220,000.

Mirum Pharmaceuticals Stock Performance

NASDAQ:MIRM opened at $39.00 on Tuesday. Mirum Pharmaceuticals has a 1-year low of $23.14 and a 1-year high of $45.23. The stock has a 50 day simple moving average of $40.80 and a 200 day simple moving average of $32.54. The company has a current ratio of 3.28, a quick ratio of 3.09 and a debt-to-equity ratio of 1.34. The stock has a market cap of $1.84 billion, a P/E ratio of -10.51 and a beta of 1.14.

Mirum Pharmaceuticals (NASDAQ:MIRM) last released its quarterly earnings data on Wednesday, August 7th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.47) by ($0.05). The firm had revenue of $77.90 million during the quarter, compared to analyst estimates of $75.03 million. Mirum Pharmaceuticals had a negative net margin of 40.34% and a negative return on equity of 43.47%. The business’s quarterly revenue was up 107.7% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.92) EPS. Research analysts anticipate that Mirum Pharmaceuticals will post -1.75 earnings per share for the current year.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.